T1	Participants 614 674	10,010 patients at 135 centers in 23 countries were enrolled
T2	Participants 508 601	patients with, or at risk for, atherosclerotic disease who were undergoing noncardiac surgery
T3	Participants 722 883	patients were randomly assigned to receive clonidine (0.2 mg per day) or placebo just before surgery, with the study drug continued until 72 hours after surgery.
